Stock Region Market Analysis and Watchlist Newsletter: The Autumn 2026 Crucible
The stocks featured in this report were previously delivered in our trading room in real-time. To access Stock Region’s real-time trade ideas, then be sure to purchase a membership now.
Disclaimer: The following publication is provided by Stock Region for educational and informational purposes only. The information contained herein does not constitute financial, legal, or investment advisory services. Equities discussed carry inherent risks, including the potential for total loss of capital. Market participants must conduct independent due diligence and consult with registered financial professionals before executing any transactions.
The Macroeconomic Meatgrinder: Small-Caps Navigating a Hostile Reality
The financial landscape of September and early October 2026 presents a theater of ruthless volatility, demanding extreme vigilance and an iron stomach from market participants. The broader macroeconomic data reveals a deeply fractured equity market where mega-cap technology and the “Magnificent Seven” continue to mask the visceral, agonizing pain experienced across the small- and micro-cap sectors. The Russell 2000 Index, long considered the truest barometer of domestic economic vitality, endured a brutal 5.3% monthly decline in September—representing its most severe monthly contraction since the tariff-induced tremors of March 2025.
The primary antagonist in this excruciating narrative is the relentless, suffocating march of U.S. Treasury yields. The benchmark 10-year yield surged a staggering 54 basis points to reach a daunting 5.29% in late September, marking its most aggressive monthly ascent in four long years. Concurrently, crude oil prices exhibited extreme volatility, temporarily breaching the $105 threshold before settling into the $90 range, injecting a fresh wave of inflationary terror into the economic discourse. For small-cap equities—which inherently rely on external financing, frequent equity raises, and floating-rate debt—this violent tightening of financial conditions acts as a strangling headwind. When the cost of capital skyrockets to these levels, the fundamental viability of pre-revenue biotechnology firms, early-stage artificial intelligence infrastructure plays, and capital-intensive clean energy projects is immediately called into question.
It is profoundly frustrating for seasoned market observers to watch the promised “small-cap premium” completely disintegrate. Over the past decade, investors in instruments like the iShares Russell 2000 ETF have absorbed a standard deviation of nearly 20% and a beta of 1.24, taking on massive uncompensated risk while drastically underperforming the S&P 500. Uncompensated risk is the silent killer of portfolios, and the recent FTSE Russell index reconstitution only further complicated matters. The June 2026 reconstitution saw unprecedented shifts in sector weightings and factor exposures, with the small-cap indices heavily weighted toward cash-burning healthcare and biotechnology companies.
Yet, within this crucible of capitulation lies extraordinary, generation-defining opportunity for the discerning analyst. As panic dictates indiscriminate selling, fundamentally sound enterprises with imminent commercial catalysts, brilliant strategic pivots, or non-dilutive funding achievements are frequently mispriced. To navigate this chaos, wisdom remains the ultimate currency. As the ancient text of Ecclesiastes 11:2 advises, “Divide your investments among many places, for you do not know what risks might lie ahead.” This timeless principle of diversification and risk management serves as a foundational anchor. Diligence—manifested through the meticulous examination of SEC filings, clinical trial data, and balance sheet mechanics—separates the enduring market participant from the speculative gambler. The following analysis tears down the complex corporate maneuvers of the past week, exposing the raw, unfiltered truth behind the ticker symbols.
The Agony and Ecstasy of Corporate Restructurings
Few events in the micro-cap space elicit as visceral a market reaction as a company fighting for its sheer survival through aggressive financial engineering. The recent developments surrounding Beneficient ($BENF) stand as a breathtaking testament to this phenomenon. On September 23, 2026, the alternative asset liquidity provider announced a radical strategy designed to completely overhaul a deeply distressed balance sheet. The equity exploded, registering a mesmerizing 433% gain by the close of the session, driven by massive volume that exceeded 163,000 times its daily average.
The architecture of this proposed corporate resurrection is breathtaking in its audacity. Beneficient seeks to eliminate approximately $130 million in purported principal and accrued interest tied to HCLP debt, alongside extinguishing roughly $88 million in additional claimed obligations. Crucially, this strategy aims to entirely sever the company’s ties with its former CEO, Brad Heppner, whose impending October 2026 sentencing has cast a long, dark shadow over the enterprise. The proposed consensual resolution involves converting all Heppner-related equity interests—including a massive $850 million preferred equity liquidation preference—into a mere 162,132 Class A common shares. Furthermore, the plan would terminate Heppner’s Class B super-voting shares, effectively stripping away his board appointment rights and dismantling a massive dilution overhang that has historically paralyzed institutional investment.
While the market’s euphoric reaction is understandable—successful execution would leave the company virtually debt-free—the absolute absurdity of the current valuation disconnect demands caution. The company explicitly stated that no definitive agreement has been signed. If a consensual resolution is not achieved prior to the October 21 sentencing date, Beneficient is prepared to engage in protracted, bloody litigation. With total liabilities hovering near $344.5 million against a deeply negative stockholders’ equity of -$210.4 million prior to this announcement, the stock remains a highly volatile restructuring play rather than a traditional value investment. Furthermore, the looming shadow of a potential class-action lawsuit investigation by the Rosen Law Firm adds an additional layer of agonizing complexity.
In a similarly dramatic, yet operationally different vein, INLIF Limited ($INLF) reported its first-half 2026 financial results, posting a seemingly astronomical EPS of $10.01 per share. This headline figure requires immediate, cynical contextualization. The massive EPS is heavily skewed by a brutal 1-for-200 reverse share consolidation executed in July 2026, which drastically reduced the weighted average outstanding share count to a mere 100,826 shares for the reporting period. It is infuriating how reverse splits distort historical comparability, yet beneath the mathematical optical illusions, the operational turnaround is highly legitimate. INLIF generated $12.94 million in revenue for the first half of 2026, a solid 26% year-over-year increase. More importantly, the company successfully transitioned from a net loss of $1.98 million in the prior year to a net income of $1.01 million. This profitability was driven by a massive expansion in gross profit margin, which more than doubled to 35.95% from 17.50%. The introduction of $3.36 million in new sales derived from intelligent equipment utilized in lithium-battery manufacturing highlights a brilliant strategic diversification away from legacy raw material sales.
The theme of financial engineering extends to Interactive Strength ($TRNR), which published a highly compelling Q2 2026 shareholder letter showcasing explosive fundamental growth. Astonishingly, the equity suffered a severe, counter-intuitive 10% drawdown on the day of the announcement. The manufacturer of specialty fitness equipment reported a staggering 445% year-over-year revenue increase, while gross margins expanded dramatically to 48%, up from 31% in the first quarter. Highlighting its impending acquisition of the connected stair-climbing brand STEPR and raising 2026 pro forma revenue guidance to over $50 million, the recent price action appears entirely detached from the underlying fundamental reality. This disconnect exemplifies the broken nature of micro-cap liquidity, where algorithmic selling can temporarily blind the market to exceptional operational execution.
Corporate maneuvers to unlock trapped value are also accelerating. Knorex ($KNRX) initiated a highly strategic carve-out of its AscendX publisher monetization unit, placing it into a separately capitalized business with external venture investors while retaining a minority stake [cite: 15]. This brilliant structural shift allows the parent company to participate in future upside while offloading the cash burn required to scale the unit globally [cite: 15]. Meanwhile, TNL Mediagene ($TNMG) entered into a definitive agreement to divest its Japanese business operations via a Management Buyout (MBO). Shedding non-core, geographically disparate assets allows the digital media conglomerate to repatriate capital and streamline operational focus. On the jurisdictional front, WISeKey ($WKEY) confirmed the planned completion of its strategic redomiciliation from Switzerland to the British Virgin Islands via a merger with WISeQey Corp., trading under the new ticker “$WQEY” beginning October 5, 2026. Redomiciling to a highly flexible, tax-efficient jurisdiction like the BVI is often a precursor to aggressive M&A activity or the spin-off of distinct corporate assets. Finally, Cycurion ($CYCU) officially regained compliance with the Nasdaq bid price requirement, removing a massive psychological overhang that had been suppressing institutional accumulation and allowing management to finally focus on scaling its cybersecurity services without the looming threat of delisting.
The Artificial Intelligence and Edge Computing Mania
The evolution of KIDZ AI ($KIDZ) represents one of the most aggressive, almost schizophrenic pivots witnessed in the 2026 fiscal year. Originally operating under the moniker Classover Holdings as a K-12 tutoring platform, the company is frantically shedding its legacy identity to emerge as a formidable player in the global GPU-as-a-Service (GPUaaS), artificial intelligence data center ecosystem, and autonomous mobility. The sheer scope of this ambition is both awe-inspiring and terrifying.
The financial architecture supporting this transition is immense. The company recently secured a massive amendment to its $500 million secured convertible financing facility, expanding the permitted use of proceeds to aggressively fund acquisitions, strategic investments, and the deployment of high-density AI infrastructure. This capital war chest is already being deployed at a blistering pace. The company announced a strategic agreement to acquire a 2.0% minority equity stake in Huading Development Co., the owner and operator of Cambodia’s national Tier III cloud data center in Phnom Penh. This strategic beachhead in Southeast Asia secures a three-year right of first refusal to lease up to 1 megawatt of data center load, locking in priority access to critical power infrastructure essential for housing high-performance GPU compute clusters. Adding to the spectacle, the company submitted a fleet procurement intention for 500 Tesla Robotaxis to launch an autonomous fleet operations strategy.
Further cementing its structural credibility in the hardware domain, KIDZ AI recently secured Bronze membership in the Open Compute Project (OCP), a global collaborative community initiated by Meta Platforms. This membership grants direct engagement with industry-leading technical specifications concerning high-density rack design, advanced liquid cooling, and power architecture. Financially, the legacy pivot is evident: Q2 2026 service revenue dropped 34% to $0.48 million as customer acquisition spend was redirected, but disciplined cost controls narrowed the net loss by 35%. With stockholders’ equity surging 163% to $9.95 million and total liabilities plummeting, the balance sheet has been effectively weaponized for the AI era.
In the deep tech wearables sector, Wearable Devices ($WLDS) secured a highly coveted Notice of Allowance from the China National Intellectual Property Administration for a patent covering its pressure-based gesture control technology. This is a monumental commercial enabler. The technology utilizes surface nerve-conduction signals (surface electromyography) to measure the precise intensity of a gesture, distinguishing between a continuous pressure-based control mechanism and a simple binary finger tap. This nuanced, proportional-control interaction serves as the critical “intent layer” required for seamless operation of extended reality (XR) headsets, spatial computing interfaces, and humanoid robotics. With a broader portfolio comprising 14 patent matters across the U.S., China, and South Korea, the company is systematically building an impenetrable intellectual property moat. However, investors must balance this technological triumph against recent SEC filings, including a massive $75 million shelf registration that points toward inevitable future equity dilution.
The intersection of AI, infrastructure, and physical space continues to accelerate. FingerMotion ($FNGR) is aggressively building out its physical AI infrastructure footprint, signing a binding agreement alongside BlueFlare to acquire a 20-acre site in Hanna, Alberta [cite: 26, 27]. Designated as Hanna Campus #1, this site will house a 6 Megawatt AI inference compute data center, powered by a brilliant hybrid mix of 3 MW local grid supply and 3 MW behind-the-meter natural gas generation [cite: 26]. This nimble deployment strategy bypasses the multi-year grid interconnection delays plaguing larger hyperscalers. At the edge of the network, Veea ($VEEA) secured a major infrastructure agreement with TROLLEE for the phased deployment of its VEEAONE edge computing platform across 1,000 unattended smart retail stores. Edge computing is the critical enabler for cashier-less retail, requiring ultra-low latency data processing that centralized cloud architectures simply cannot provide.
In the realm of autonomous military tech, VisionWave Holdings ($VWAV) released a breathtaking corporate overview detailing its STRATUM autonomous ground systems and tactical aerial ecosystem. The company is pioneering a highly integrated defense architecture where unmanned ground vehicles (UGVs) like the VARAN and SCOUT interoperate seamlessly with TALON aerial drones via the AI-enabled STRATUM Command layer. By fusing radar, RF sensing, and optical intelligence across domains, VisionWave is directly addressing the modern military’s voracious demand for multi-mission, attritable autonomous platforms. This was emphatically validated by a massive $20 million purchase order for 200 STRATUM VARAN UGVs.
The necessity of biometric security in this hyper-connected era resulted in a massive 110% intraday equity surge for BIO-key International ($BKYI) following the announcement of a strategic partnership with the Dubai-based Al Majlis Group. The alliance is designed to aggressively expand BIO-key’s biometric-centric Identity and Access Management (IAM) platform across the United Arab Emirates and Saudi Arabia. As the Arabian Gulf accelerates its digital transformation, identity security has become the absolute foundational perimeter of national cybersecurity. BIO-key’s PortalGuard solution is perfectly suited for the highly regulated defense, government, and critical infrastructure sectors of the Middle East. Concurrently, BIO-key brilliantly cleaned up its balance sheet by exchanging $416,315 of outstanding notes for 247,805 newly issued common shares, replacing suffocating debt with equity.
The Life Science Grind: Validation Amidst the Carnage
In the biotechnology sector, capital preservation and non-dilutive funding are the absolute lifeblood of survival, particularly during periods of elevated interest rates that crush pre-revenue valuations. SCYNEXIS ($SCYX) delivered a masterclass in pipeline validation on September 28, 2026, announcing the execution of a monumental, paradigm-shifting contract with the Biomedical Advanced Research and Development Authority (BARDA). It is an absolute joy to witness a small-cap biotech secure its future without destroying its capitalization table.
The BARDA contract provides potential total non-dilutive funding of up to $214 million to support the development of SCY-247, the company’s second-generation triterpenoid (fungerp) antifungal candidate. The initial base period immediately unlocks approximately $18.5 million to advance both oral and intravenous formulations of SCY-247 into Phase 2 clinical trials targeting invasive candidiasis. The structural mechanics of this cost-share agreement are exceptionally favorable. BARDA will support eligible direct, general, and administrative expenses, allowing SCYNEXIS to fund its share of near-term program costs entirely within its existing operational runway, which safely extends into 2029. Furthermore, the contract features up to six options that could extend the partnership for ten years, potentially funding SCY-247 all the way through New Drug Application (NDA) submissions to the FDA. SCY-247 addresses a terrifying public health crisis: the rise of multi-drug resistant fungal pathogens, possessing a differentiated mechanism of action with proven in vitro efficacy against resistant strains.
The medical device landscape also provided highly encouraging developments. Profusa ($PFSA) achieved a critical, deeply challenging regulatory milestone, receiving a positive decision from the European notified body GMED regarding ISO 13485 certification for its quality management system. This directly clears the path for the remaining Medical Device Regulation (MDR) conformity assessments required for the CE marking of the Lumee Oxygen Platform. Designed to provide continuous, real-time tissue oxygen monitoring via a proprietary, injectable hydrogel biosensor smaller than a grain of rice, Lumee targets critical limb ischemia (CLI) and remote wound care management. The analytical community eagerly awaits the official CE mark, targeted for April 2026, which would unlock the massive 27-nation EU market ahead of a planned U.S. launch.
In the neurological space, Firefly Neuroscience ($AIFF) announced a highly synergistic partnership with NeuroSigma to expand access to the Monarch eTNS System, the first FDA-cleared, non-drug treatment for pediatric ADHD. Firefly will leverage its nationwide network of clinicians currently utilizing the Evoke EEG brain-function assessment platform to distribute the Monarch device. With over 6.5 million children diagnosed with ADHD in the U.S., and nearly a third receiving no specific treatment due to intense parental hesitation regarding stimulant medications, the demand for non-pharmacological interventions is surging violently. The integration of NeuroSigma’s at-home therapy with Firefly’s AI-driven diagnostic monitoring creates a compelling, closed-loop neurological care ecosystem that could rapidly disrupt traditional prescribing habits.
Glucotrack / Lōkahi Therapeutics ($GCTK) continues to aggressively build out its actual intelligence-driven (ai²) platform. Following a strategic transformation, the Lōkahi subsidiary expanded its ai² PIPELINE into three dedicated divisions: Pipeline, Talent, and Accelerator, officially shifting from an internal asset engine to a revenue-generating powerhouse. The company has rapidly scaled its university collaborations to 13 institutions, securing partnerships with Pepperdine E2B, San Diego State University, and internationally with Universität Paderborn. These academic partnerships provide a brilliant, low-cost analytical workforce to perform exhaustive due diligence on thousands of abandoned or deprioritized late-stage pharmaceutical assets. Having evaluated over 12,000 programs on a shoestring $33,000 budget and advanced five into active business discussions, the model proves absurdly capital-efficient. A recent $3 million public offering provides the necessary runway to execute the upcoming clinical program for LT-100 (a biologic for osteoarthritis knee pain).
The broader life sciences sector displayed a flurry of incremental yet vital progress. Connect Biopharma ($CNTB) delivered highly encouraging preliminary Phase 2 data for Rademikibart as an add-on treatment for adults suffering from acute exacerbations in COPD with Type 2 inflammation. Given the massive global prevalence of COPD, positive efficacy signals in this indication command intense pharmaceutical partnering interest. Valion Bio ($VBIO) successfully formulated Oral Mucosal Entolimod in collaboration with Shear Kershman Laboratories, a breakthrough expected to yield a multi-fold expansion of the drug’s long-term commercial opportunity by bypassing the traditional hurdles of gastrointestinal degradation. Nexalin Technology ($NXL) executed a definitive exclusive distribution and local manufacturing agreement covering Brazil and South America, marking a pivotal transition from clinical validation to tangible commercial revenue generation in highly populated emerging markets. Scienture ($SCNX) announced that its hypertension drug Arbli has been successfully added to the formularies of three major U.S. pediatric academic medical centers, unlocking a market segment that commands approximately 72 million prescriptions annually. Autonomix Medical ($AMIX) strengthened its intellectual property fortress, receiving Canadian Patent No. 3,183,802 for its catheter-based nerve treatment technology. Finally, DataMeds AI / Tollo Health ($MEDS) showcased impressive commercial traction, reporting that its Corexa Pharmacy subsidiary surpassed $1 million in monthly revenue, while simultaneously launching the ‘Health Lives Here’ mobile application to bridge digital health monitoring with physical pharmacy fulfillment. HCW Biologics ($HCWB) successfully priced a $1.5 million private placement, ensuring the lights stay on to advance preclinical pipelines. Similarly, SRX Global / Onconetix ($ONCO) provided an update regarding the liquidation of two portfolio investments, aggressively redirecting capital into a fresh investment in Nasdaq-listed Onconetix, demonstrating active portfolio recycling into high-conviction oncology therapeutics. Evogene ($EVGN) was granted a 180-day extension by Nasdaq to regain minimum bid price compliance, offering a crucial lifeline to effectuate a turnaround or reverse split.
Energy Transition, Mobility, and Industrial Resurgence
The global transition toward electrification and sustainable infrastructure requires a staggering diversification of industrial capacity. CBAK Energy Technology ($CBAT) forcefully positioned itself at the absolute vanguard of this transition by signing a landmark investment agreement with the Nanjing Gaochun Economic Development Zone to construct a massive 12 GWh large cylindrical battery project. The strategic brilliance of this expansion lies in its dual-chemistry compatibility. The planned production lines are being meticulously designed to manufacture both sodium-ion and lithium-ion cells. This phenomenal flexibility effectively hedges the company’s massive capital expenditure against fluctuating raw material costs. Sodium-ion technology is rapidly gaining violent market traction due to its superior fast-charging capabilities, exceptional wide-temperature performance, and complete independence from scarce lithium and cobalt resources. CBAK is already undergoing rigorous customer testing of its 32140 NH-7Ah sodium-ion cells across residential storage, portable energy, and electric two-wheeler applications.
In addition to the long-term 12 GWh project, which is slated to advance in the second half of 2027 subject to financing, the company is executing an immediate 6 GWh expansion at its existing Nanjing facility to meet voracious demand for its Model 60150 large cylindrical cells. Set for the second half of 2026, this expansion will push the existing facility’s total annual capacity to 10.5 GWh. At full utilization, the financial implications are staggering: the 6 GWh expansion alone could generate up to $400 million in additional annual revenue, while the 12 GWh project could add an astonishing $741 million annually. The equity surged over 13% on the announcement, reflecting well-deserved institutional recognition.
The autonomous oceans sector provided a sobering reminder of the cost of innovation. Nauticus Robotics ($KITT) filed an 8-K detailing a non-binding Letter of Intent (LOI) with an unnamed strategic investor for a private placement equity investment of up to $50 million. While a $50 million injection would fundamentally secure the balance sheet for the autonomous subsea robotics developer, the filing contained explicit, terrifying language warning that the transaction could result in “significant shareholder dilution and/or a change of control”. The board’s decision to consider an independent financial advisor suggests that negotiations are highly predatory, and existing shareholders must brace for potential structural devastation in the capitalization table.
Traditional infrastructure provided moments of pure euphoria. Southland Holdings ($SLND) experienced a massive 26% pre-market surge following the announcement that its subsidiary, Oscar Renda Contracting, secured a $71 million contract. The project entails the installation of 14 miles of 42-inch welded steel water pipeline in the Southwest. For a company with a market capitalization hovering around a mere $33 million and suffering from deeply negative operating margins (-54.61%), a single contract of this magnitude is deeply transformative, injecting a vital lifeline of backlog into its Civil segment.
In the mobility and aviation sectors, Surf Air Mobility ($SRFM) executed sweeping operational changes, appointing Barrett Brown as President of SurfOS and signing a highly lucrative OperatorOS Contract with SkyDance Air. Monetizing the software operating system (SurfOS) represents a brilliant, desperate transition toward high-margin, recurring SaaS revenue, escaping the brutal capital-intensive nature of physical regional air mobility operations. Faraday Future ($FFAI) announced a profound strategic metamorphosis of its own, formally upgrading its corporate structure from a pure-play EV manufacturer to a “Robotaxi and EAI Cabin shared mobility operations company.” This pivot explicitly acknowledges the agonizing cash burn of traditional automotive manufacturing, embracing the high-margin ecosystem of autonomous fleet operations.
On the environmental and logistics fronts, MindWave Innovations ($APUS) executed a landmark agreement to build and operate AQUAEChain. This blockchain-based platform is designed specifically for the issuance and management of insured ALCI (Aquatic Life Carbon Inset) credits. As global ESG mandates tighten, verifiable, blockchain-secured carbon credits command an immense premium. Greenland Energy Company ($GLND) announced the vital extension of the Jameson Land Farm-Out Agreement with 80 Mile plc, ensuring that capital commitments and exploratory drilling schedules remain intact in harsh-environment exploration zones. Green Circle Decarbonize Technology ($GCDT) formally submitted tender proposals for massive chiller replacement engineering and air-conditioning retrofits in Hong Kong, chasing substantial, multi-year revenue visibility. Haoxin Holdings ($HXHX) unveiled a U.S. Logistics Acquisition Initiative to penetrate the highly fragmented U.S. freight market, bypassing the arduous process of organic market entry. AsiaStrategy ($SORA) executed a Memorandum of Understanding with Plume Network to advance real-world asset (RWA) tokenization across Asia, positioning itself at the absolute forefront of the decentralized finance (DeFi) infrastructure movement. Furthermore, TGE ($TGE) reported a stunning profit surge of 9.9 times, with total assets ballooning to US$1.8 billion. Finally, the algorithmic volume alerts triggered on $SDEV, with a massive surge pushing the price to $2.92, serve as a stark reminder that in the micro-cap underworld, unexplained volume spikes frequently precede unannounced corporate actions or pending regulatory clearances.
Final Analytical Perspectives
The early days of Q4 2026 demand a highly tactical, almost militant approach to capital allocation. The macroeconomic environment—characterized by restrictive central bank policies, elevated sovereign yields, and a completely broken small-cap premium—will mercilessly eviscerate equities burdened by unmanageable debt and perpetual cash burn. Conversely, this very same toxic environment creates extraordinary, asymmetrical leverage for companies executing brilliant financial engineering (like Beneficient), securing massive non-dilutive government funding (like SCYNEXIS), or pioneering disruptive hardware architectures (like KIDZ AI and CBAK Energy).
The successful market participant must ignore the agonizing noise of the broader indices and focus ruthlessly on the granular details contained within SEC filings, clinical data readouts, and patent approvals. Fortunes in the micro-cap space are not made by passively tracking the S&P 500; they are forged by identifying the structural transformations occurring deep within the 8-K filings of companies the broader market has temporarily abandoned.
Disclaimer: The analysis and information provided in this Stock Region newsletter are intended for educational and informational purposes only and do not constitute financial, investment, or legal advice. Investing in financial markets, particularly in micro-cap, small-cap, and biotechnology equities, involves a high degree of risk and may result in the partial or total loss of principal. Forward-looking statements are subject to material uncertainties. Market participants must consult with a certified financial advisor and conduct independent, exhaustive due diligence prior to making any investment decisions. Stock Region and its affiliates accept no liability for any financial losses incurred as a result of utilizing the information presented herein.